4.6 Article

Dioxomolybdenum(VI) complexes of 2-hydroxy-4-benzyloxybenzaldehyde thiosemicarbazones alkylated via N or S atoms. Synthesis, characterization, antioxidant and xanthine oxidase inhibition performance

Journal

JOURNAL OF MOLECULAR STRUCTURE
Volume 1295, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.molstruc.2023.136604

Keywords

Dioxomolybdenum(VI); Thiosemicarbazone; Antioxidant activities; Radical scavenging activity; Xanthine oxidase

Ask authors/readers for more resources

In this study, a series of long alkyl chain-substituted dioxomolybdenum(VI) complexes were successfully synthesized and characterized. Complex VII exhibited significant XO inhibitory activity and has the potential to be used in the treatment of XO-based disorders.
Using the synthesis method, we produced a series of 2-hydroxy-4-benzyloxybenzylidene N-or S-alkyl chains substituted thiosemicarbazones and their dioxomolybdenum(VI) complexes containing long alkyl chains (pentyl, hexyl, heptyl, and octyl). A series of dioxomolybdenum(VI) complexes with 2-hydroxy-4-benzyloxybenzylidene thiosemicarbazones substituted by long alkyl chains, pentyl, hexyl, heptyl, and octyl, on the N-or S atoms were synthesized. Analytical and spectroscopic techniques were used to characterize the compounds. As a representative molecule, the molecular structure of complex I named cis-dioxo-(N1-2-hydroxy-4-benzyloxybenzylidene-N4-pentylthiosemicarbazonato)-methanol-molybdenum(VI) was identified by single crystal X-ray diffraction. Using the method of cupric reducing antioxidant capacity, the ONN donor thiosemicarbazones (LV-LVIII) were found to have higher trolox equivalent antioxidant capacity values than those with ONS (LI-LIV). Furthermore, the inhibitory activities of xanthine oxidase and the scavenging effects of the compounds on the hydroxyl radical were examined. Complex VII was the most effective XO inhibitor with an IC50 value of 33.41 mu M in similar to allopurinol as a potential XO inhibitor (IC50: 33.14 mu M), and it can be used as XO inhibitor in treatment of XObased disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available